Fibrogen Inc (FGEN)

$1.15

-0.02

(-1.71%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Fibrogen Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 44.31M → 27.13M (in $), with an average decrease of 20.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -87.68M → -56.23M (in $), with an average increase of 25.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 142.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 234.9% return, outperforming this stock by 329.2%

Performance

  • $1.06
    $1.18
    $1.15
    downward going graph

    7.83%

    Downside

    Day's Volatility :10.17%

    Upside

    2.54%

    downward going graph
  • $0.33
    $20.44
    $1.15
    downward going graph

    71.02%

    Downside

    52 Weeks Volatility :98.37%

    Upside

    94.37%

    downward going graph

Returns

PeriodFibrogen IncSector (Health Care)Index (Russel 2000)
3 Months
30.9%
-0.4%
0.0%
6 Months
109.17%
8.5%
0.0%
1 Year
-94.24%
4.2%
-1.2%
3 Years
-94.35%
13.9%
-19.2%

Highlights

Market Capitalization
115.6M
Book Value
- $2.07
Earnings Per Share (EPS)
-2.92
PEG Ratio
0.0
Wall Street Target Price
1.75
Profit Margin
-192.37%
Operating Margin TTM
-381.26%
Return On Assets TTM
-35.54%
Return On Equity TTM
-1015.79%
Revenue TTM
147.8M
Revenue Per Share TTM
1.52
Quarterly Revenue Growth YOY
-21.0%
Gross Profit TTM
-159.2M
EBITDA
-283.9M
Diluted Eps TTM
-2.92
Quarterly Earnings Growth YOY
0.54
EPS Estimate Current Year
-1.29
EPS Estimate Next Year
-0.43
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
-0.4

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 10 Wall street analysts offering stock ratings for Fibrogen Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
5
5
8
Sell
5
5
4

Analyst Forecast

What analysts predicted

Upside of 52.17%

Current $1.15
Target $1.75

Company Financials

FY18Y/Y Change
Revenue
213.0M
↑ 69.46%
Net Income
-86.4M
↓ 31.52%
Net Profit Margin
-40.58%
↑ 59.85%
FY19Y/Y Change
Revenue
256.6M
↑ 20.48%
Net Income
-77.0M
↓ 10.93%
Net Profit Margin
-30.0%
↑ 10.58%
FY20Y/Y Change
Revenue
176.3M
↓ 31.28%
Net Income
-189.3M
↑ 145.93%
Net Profit Margin
-107.36%
↓ 77.36%
FY21Y/Y Change
Revenue
235.3M
↑ 33.46%
Net Income
-291.0M
↑ 53.75%
Net Profit Margin
-123.68%
↓ 16.32%
FY22Y/Y Change
Revenue
140.7M
↓ 40.19%
Net Income
-295.2M
↑ 1.44%
Net Profit Margin
-209.78%
↓ 86.1%
FY23Y/Y Change
Revenue
147.8M
↑ 4.99%
Net Income
-284.2M
↓ 3.72%
Net Profit Margin
-192.37%
↑ 17.41%
Q3 FY22Q/Q Change
Revenue
15.7M
↓ 47.21%
Net Income
-92.1M
↑ 25.78%
Net Profit Margin
-585.05%
↓ 339.5%
Q4 FY22Q/Q Change
Revenue
34.4M
↑ 118.41%
Net Income
-66.5M
↓ 27.81%
Net Profit Margin
-193.37%
↑ 391.68%
Q1 FY23Q/Q Change
Revenue
36.2M
↑ 5.22%
Net Income
-77.5M
↑ 16.62%
Net Profit Margin
-214.32%
↓ 20.95%
Q2 FY23Q/Q Change
Revenue
44.3M
↑ 22.56%
Net Income
-87.7M
↑ 13.13%
Net Profit Margin
-197.84%
↑ 16.48%
Q3 FY23Q/Q Change
Revenue
40.1M
↓ 9.44%
Net Income
-63.6M
↓ 27.45%
Net Profit Margin
-158.51%
↑ 39.33%
Q4 FY23Q/Q Change
Revenue
27.1M
↓ 32.38%
Net Income
-56.2M
↓ 11.61%
Net Profit Margin
-207.21%
↓ 48.7%
FY18Y/Y Change
Total Assets
880.6M
↓ 2.01%
Total Liabilities
352.1M
↑ 11.36%
FY19Y/Y Change
Total Assets
857.4M
↓ 2.63%
Total Liabilities
322.0M
↓ 8.56%
FY20Y/Y Change
Total Assets
826.8M
↓ 3.56%
Total Liabilities
385.4M
↑ 19.69%
FY21Y/Y Change
Total Assets
773.8M
↓ 6.41%
Total Liabilities
544.7M
↑ 41.34%
FY22Y/Y Change
Total Assets
610.1M
↓ 21.16%
Total Liabilities
611.6M
↑ 12.27%
FY23Y/Y Change
Total Assets
423.5M
↓ 30.58%
Total Liabilities
585.7M
↓ 4.23%
Q3 FY22Q/Q Change
Total Assets
608.8M
↓ 11.35%
Total Liabilities
562.6M
↓ 0.08%
Q4 FY22Q/Q Change
Total Assets
610.1M
↑ 0.21%
Total Liabilities
611.6M
↑ 8.71%
Q1 FY23Q/Q Change
Total Assets
538.5M
↓ 11.73%
Total Liabilities
567.4M
↓ 7.22%
Q2 FY23Q/Q Change
Total Assets
515.1M
↓ 4.35%
Total Liabilities
575.4M
↑ 1.41%
Q3 FY23Q/Q Change
Total Assets
460.4M
↓ 10.62%
Total Liabilities
575.6M
↑ 0.03%
Q4 FY23Q/Q Change
Total Assets
423.5M
↓ 8.01%
Total Liabilities
585.7M
↑ 1.75%
FY18Y/Y Change
Operating Cash Flow
-76.1M
↑ 14.48%
Investing Cash Flow
-522.1M
↓ 847.32%
Financing Cash Flow
13.9M
↓ 97.21%
FY19Y/Y Change
Operating Cash Flow
-78.7M
↑ 3.36%
Investing Cash Flow
120.0M
↓ 122.99%
Financing Cash Flow
-4.3M
↓ 130.99%
FY20Y/Y Change
Operating Cash Flow
81.6M
↓ 203.68%
Investing Cash Flow
452.5M
↑ 277.02%
Financing Cash Flow
13.3M
↓ 410.3%
FY21Y/Y Change
Operating Cash Flow
-82.2M
↓ 200.77%
Investing Cash Flow
-427.0M
↓ 194.36%
Financing Cash Flow
-563.0K
↓ 104.22%
FY22Y/Y Change
Operating Cash Flow
-145.9M
↑ 77.46%
Investing Cash Flow
89.1M
↓ 120.87%
Financing Cash Flow
46.8M
↓ 8408.35%
Q3 FY22Q/Q Change
Operating Cash Flow
-51.9M
↑ 56.91%
Investing Cash Flow
44.8M
↑ 158.79%
Financing Cash Flow
-1.1M
↓ 152.32%
Q4 FY22Q/Q Change
Operating Cash Flow
-52.5M
↑ 1.22%
Investing Cash Flow
1.1M
↓ 97.56%
Financing Cash Flow
48.7M
↓ 4557.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-101.6M
↑ 93.46%
Investing Cash Flow
103.5M
↑ 9367.7%
Financing Cash Flow
31.5M
↓ 35.31%
Q2 FY23Q/Q Change
Operating Cash Flow
-110.6M
↑ 8.84%
Investing Cash Flow
-14.3M
↓ 113.8%
Financing Cash Flow
91.5M
↑ 190.72%
Q3 FY23Q/Q Change
Operating Cash Flow
-84.5M
↓ 23.54%
Investing Cash Flow
54.2M
↓ 479.54%
Financing Cash Flow
-22.0K
↓ 100.02%

Technicals Summary

Sell

Neutral

Buy

Fibrogen Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Fibrogen Inc
Fibrogen Inc
-51.27%
109.17%
-94.24%
-94.35%
-97.54%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Fibrogen Inc
Fibrogen Inc
NA
NA
0.0
-1.29
-10.16
-0.36
NA
-2.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Fibrogen Inc
Fibrogen Inc
Sell
$115.6M
-97.54%
NA
-192.37%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • PRIMECAP Management Company

    14.65%
  • Armistice Capital, LLC

    9.89%
  • BlackRock Inc

    7.29%
  • Vanguard Group Inc

    7.13%
  • Jacobs Levy Equity Management, Inc.

    2.59%
  • Acadian Asset Management LLC

    2.50%

Corporate Announcements

  • Fibrogen Inc Earnings

    Fibrogen Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.

Organization
Fibrogen Inc
Employees
486
CEO
Mr. Thane Wettig
Industry
Health Technology

FAQs